Distinguishing Tumor Cells from Immune Cells and the Implications of Cytoplasmic Staining

Join Agilent CDx Pathologist, Dr. Kristopher Kersch, as he walks through Lung Cancer and Esophageal Cancer cases stained with PD-L1 IHC 22C3 pharmDx. This video covers approaches for distinguishing between immune cells and tumor cells in cases stained with PD-L1 IHC 22C3 pharmDx, how cytoplasmic staining affects interpretation using both Tumor Proportion Score (TPS) and Combined Positive Score (CPS).​

The Spotlight Video Series walks you through CPS principles and scoring strategies for cases stained with PD-L1 IHC 22C3 pharmDx. Through this engaging series, Agilent PD-L1 experts will help you to confidently:​

• Evaluate H&E, NCR, and PD-L1 slides for adequacy ​
• Understand inclusion/exclusion criteria and other core principles of Combined Positive Score (CPS)​
• Determine the best approaches for scoring cases based on specific characteristics and features​
• Navigate challenging morphology and staining characteristics​

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.​​D0113767_1.00​